Novavax Asks WHO to Grant Emergency Clearance for Covid Shot
(Bloomberg) -- Novavax Inc. said it has filed with the World Health Organization for an emergency-use listing for its Covid-19 vaccine, a move that could help its inoculation reach more people at a time of vast global disparities in immunizations.
The company said in a statement on Thursday that the trial data submitted to the United Nations health agency shows that the shot provided 100% protection against moderate and severe disease and had 90.4% efficacy overall.
Shares of Novavax gained 4.1% in after-hours trading in New York. Through the close of trading in New York Thursday, the stock had gained 61% so far this year.
While Novavax has experienced production setbacks that prevented its shot from being a key player in the U.S. vaccination drive, it has been moving to gain access to more markets in other countries. Chief Executive Officer Stanley Erck has also said the company's vaccine could eventually be an excellent booster candidate.
An emergency clearance from the WHO could mean that Novavax would quickly be able to offer its shot in many developing countries, where access to other vaccines has been hard to come by. Along with the WHO filing, Novavax has sought clearance in the U.K., Australia, Canada, New Zealand, the European Union, India, and the Philippines, the company said.
The company, which won clearance for its shot in Indonesia earlier this week, said it plans to submit data to the U.S. Food and Drug Administration by the year-end.
Separately, Novavax reported third-quarter revenue rose 14% from a year earlier, though that figure fell short of analysts' estimates, on average, according to data compiled by Bloomberg. The company also posted a net loss of $4.31 a share.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.